In breve
Ict01 is being studied in clinical trials for people with advanced cancer, including relapsed or refractory disease and some newly diagnosed acute myeloid leukemia cases. The trials look at safety, tolerability, and early signs of anti-tumor activity, often in combination with other cancer treatments.
Punti chiave
- Ict01 is being studied in early clinical trials for people with advanced cancer, relapsed or refractory disease, and some newly diagnosed acute myeloid leukemia. The studies are in Phase 1/2, so they first focus on safety and tolerability and then on early signs of benefit. One trial looks at Ict01 alone or with pembrolizumab in advanced cancer, while another studies Ict01 with low-dose interleukin-2 and, in some cases, pembrolizumab. The trials also include combinations with venetoclax and azacitidine for acute myeloid leukemia. Main outcomes include adverse events, laboratory test changes, disease control, and remission rates.
Overview of the trials
The available data describe two interventional studies of Ict01 in cancer, both in Phase 1/2. One study is a first-in-human trial in patients with advanced-stage, relapsed/refractory cancer, and it is authorised. The other study is an open-label trial in advanced solid tumors and is completed.
Who the trials include
The first study includes patients with advanced-stage, relapsed/refractory cancer, which means cancer that is late stage and has come back or does not respond to treatment. The second study includes people with advanced solid tumors, with specific cancer types listed as metastatic castration-resistant prostate cancer, metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, metastatic or unresectable refractory melanoma, and metastatic ovarian cancer.
In the first study, the brief summary also mentions patients with relapsed/refractory advanced solid tumors or hematologic malignancies, and a part of the study focuses on newly diagnosed acute myeloid leukemia (AML). In the second study, the trial also includes advanced melanoma or pancreatic ductal adenocarcinoma in a part that combines Ict01 with low-dose subcutaneous interleukin-2 and pembrolizumab.
How the studies are designed
Both trials are interventional, which means the researchers give treatment and then measure the results. The first study is a first-in-human design, so it is the first time the treatment is being tested in people in this setting. The second study is open-label, meaning both the study team and the participants know which treatment is being used.
The first trial has an enrollment of 375, and the second trial has an enrollment of 88. In the first study, Ict01 is given intravenously, meaning through a vein. In the second study, Ict01 is also given intravenously, and the study explores different combinations across its parts.
What the trials measure
The first study mainly measures safety and tolerability by looking at treatment-emergent adverse events, serious adverse events, and treatment changes caused by side effects or other problems. It also checks laboratory test abnormalities, vital signs, electrocardiograms, and physical examination findings. These are standard ways to see whether the treatment causes medical problems during the study.
In the first study, later parts also measure disease control rate for solid tumors and complete remission rate for AML. Disease control rate includes complete response, partial response, and stable disease according to RECIST 1.1, a standard method used to measure tumor change on scans. For AML, the study uses ELN 2022 criteria and measures complete remission, complete remission with partial hematologic recovery, complete remission with incomplete hematologic recovery, and morphologic leukemia-free state.
The second study also focuses first on safety and tolerability, including dose-limiting toxicities, treatment-emergent adverse events, fatal adverse events, serious treatment-emergent adverse events, and treatment modifications or discontinuation. It additionally measures clinically significant laboratory, vital sign, ECG, and physical examination findings. Its main activity outcome is disease control rate, defined as stable disease, partial response, or complete response per RECIST.
Treatment combinations being tested
The first study tests Ict01 as monotherapy, which means alone, and also in combination with pembrolizumab, known in the trial as Keytruda. It also includes a continued treatment period to assess how long the benefit lasts in people who still have clinical benefit.
The second study tests Ict01 with low-dose subcutaneous interleukin-2, also called LDSC IL-2, and in some parts with pembrolizumab. The brief summary also mentions combinations with venetoclax and azacitidine in newly diagnosed AML in the first study record. These combinations are being explored to see whether they improve early anti-tumor activity.
Main points for patients
These trials are early cancer studies, not routine treatment programs. Their main goal is to learn whether Ict01 can be used safely and whether it shows signs of helping against cancer in advanced disease.
The studies focus on patients with difficult-to-treat cancers, including advanced solid tumors and AML. They use standard cancer research measures such as adverse events, RECIST, disease control rate, and remission criteria to judge the results.